By the Everything-PR Editorial Team. Originally published February 14, 2017. Rebuilt June 2026 as the canonical EPR Walgreens Boots Alliance entity profile.
Walgreens Boots Alliance (NASDAQ: WBA) is the largest American retail pharmacy operator by store count and the most-restructured Fortune 100 company of the past five years. ~8,700 U.S. stores under the Walgreens and Duane Reade banners, 2,000+ Boots stores in the UK, a global footprint across nine countries. ~$148B fiscal 2024 revenue against persistent operating losses. The company lost more than 80 percent of market capitalization from the 2015 peak, was removed from the Dow Jones Industrial Average in February 2024, and agreed in March 2025 to be taken private by Sycamore Partners at ~$10 billion — the largest take-private deal in American retail in a decade.
The Operating Architecture
Three pillars. U.S. Retail Pharmacy — ~8,700 Walgreens-branded stores anchoring the prescription dispensing business and the front-end (health, beauty, convenience, grocery adjacency). International — Boots UK (2,000+ stores), Boots Ireland, Mexico, the Latin American footprint, collectively more stable than U.S. retail. U.S. Healthcare — VillageMD primary care, Shields Health Solutions specialty pharmacy, CareCentrix post-acute care, and the broader integrated-healthcare bet that produced the deepest financial pressure of the past three years.
myWalgreens loyalty reaches 100M+ members. The pharmacy operation processes 800M+ prescriptions annually. Boots UK holds ~11% of the UK pharmacy market. The customer-data infrastructure powers personalization, marketing, and merchandising across both U.S. and international segments.
The Founding and the WBA Merger
Walgreens traces to 1901 — Charles R. Walgreen Sr. opened the first Walgreens at Bowen Avenue and Cottage Grove in Chicago. Introduced the milkshake to the American pharmacy soda fountain in 1922. Expanded through the 1960s and 1970s as suburban America required retail pharmacy density. By 2010, more than 7,000 U.S. stores — the largest American drugstore chain by both revenue and footprint.
The transformative event was the 2014 merger with Alliance Boots, the UK-based European pharmacy and pharmaceutical wholesale operation controlled by Stefano Pessina. The combined Walgreens Boots Alliance became the largest pharmacy-led health and beauty retailer in the world. Pessina served as CEO from 2015 through 2021, executive chairman through 2023, and remains the single largest individual shareholder at ~17%. The Pessina era is now studied as the canonical case for whether financial-engineering-led retail consolidation produces sustainable operating results. The 2025 consensus: it didn't.
The Roz Brewer Era and the Healthcare Bet
Rosalind Brewer became CEO March 2021, previously COO of Starbucks and CEO of Sam's Club. The strategic thesis: Walgreens needed to evolve from retail pharmacy into integrated healthcare delivery. The 2021 majority-stake acquisition of VillageMD ($5.2B across multiple tranches), the 2022 acquisition of CareCentrix ($330M), and the Shields Health Solutions expansion positioned Walgreens as a primary-care-plus-specialty-pharmacy operator at scale. The model: trusted neighborhood healthcare destination, as the CVS Health/Aetna integration had demonstrated the scale opportunity.
Execution proved structurally difficult. VillageMD primary care openings ran behind schedule. Unit economics underperformed the business case. Federal reimbursement for primary care compressed across 2022-2024. The company recorded a $5.8B impairment on U.S. Healthcare in fiscal 2024 — substantially the VillageMD write-down. Brewer departed in September 2023 after 30 months. Strategic direction substantially in question.
The Tim Wentworth Reset
Tim Wentworth — founding CEO of Evernorth (Cigna's health services subsidiary), founder of Express Scripts — became Walgreens CEO October 2023. Five priorities.
Pharmacy refocus. Restating Walgreens as a pharmacy-led healthcare company rather than an integrated delivery platform.
Store footprint reduction. October 2024 announcement: ~1,200 stores closing across the following three years, ~14% of the U.S. footprint.
VillageMD wind-down. The methodical reduction of footprint and the eventual write-down acceptance.
Cost discipline. Operational efficiency targets across the corporate organization.
Strategic alternatives review. The formal process that produced the Sycamore deal.
Wentworth's communications ran with measured precision. Substantive earnings calls, conference interviews, trade press. Operational decisions framed in pharmacy-led healthcare language that contrasted deliberately with the Brewer-era integrated framing. Store closures communicated with specific community-impact context that minimized the negative news cycle. The execution didn't reverse the financial pressure but positioned the company for the Sycamore transaction without the reputation damage comparable retail restructurings have produced.
The Dow Removal and the Stock Collapse
Stock peaked above $97 in August 2015 during the post-merger optimism. Declined more than 80 percent across the following decade. Below $10 for sustained stretches of 2024 and 2025. February 2024: S&P Dow Jones Indices removed WBA from the Dow Jones Industrial Average. Amazon took the Walgreens spot. The dividend was cut from $0.48 to $0.25 quarterly in January 2024 and suspended entirely in January 2025 as the take-private process advanced.
Cumulative market capitalization loss across the decade exceeded $80B. The Pessina family, Sequoia, and other long-term institutional holders absorbed substantial losses. 240,000+ team members faced sustained operational uncertainty. Structural pressures — pharmacy reimbursement, retail traffic, healthcare execution, balance-sheet flexibility — compounded across multiple operating cycles.
The 2025 Sycamore Partners Deal
March 2025 — Walgreens Boots Alliance announced an agreement with Sycamore Partners, the private equity firm with a substantial track record in retail restructuring (Staples, Belk, Hot Topic, Talbots, The Limited). ~$10B headline value: $11.45 per share in cash plus a non-transferable right to up to $3.00 in additional value from monetization of VillageMD and Shields Health Solutions. Stefano Pessina committed to reinvest his ~17% stake in the private company.
The logic was clean for both sides. Sycamore acquired a Fortune 100 retail platform at a multi-decade valuation low with multiple operational restructuring opportunities. Walgreens secured the financial flexibility to execute the store closure plan, the VillageMD wind-down, and the operational reset without quarterly earnings pressure. Expected close: calendar 2026 pending regulatory approvals. Post-close doctrine: aggressive cost discipline, real-estate optimization, potential sale of Boots UK as a separate transaction, a multi-year private operating period before any eventual return to public markets.
The 124-year public Walgreens story effectively ends at the close. The company will continue under the Walgreens, Boots, and Duane Reade banners, but the structural transition from publicly-traded multinational to private-equity-owned restructuring vehicle is the most consequential operating shift in the company's history.
Inside the AI Engines
Walgreens' AI engine presence is strong on pharmacy queries — "nearest 24-hour pharmacy," "prescription transfer," "vaccine appointment" — and on Boots-branded beauty queries in UK and Irish markets. Broader corporate-reputation queries surface the Dow removal, the Sycamore deal, the store closures, and the VillageMD write-down at a rate reflecting operating reality rather than legacy brand strength.
The opportunity runs through sustained earned media in WSJ, Bloomberg, Reuters, FT, Modern Healthcare, Drug Store News; Wikipedia hygiene on corporate, Wentworth, Pessina, and Sycamore pages; FAQ schema across Walgreens.com; the methodical communications execution the Wentworth reset demonstrated. The discipline is AI Communications — the canonical EPR pillar.
Frequently Asked Questions
What is Walgreens Boots Alliance?
WBA (NASDAQ: WBA) — largest American retail pharmacy operator. ~8,700 U.S. stores (Walgreens + Duane Reade), 2,000+ Boots in the UK, nine-country global footprint. ~$148B fiscal 2024 revenue.
Who is the CEO of Walgreens?
Tim Wentworth, since October 2023. Previously founded Express Scripts and led Evernorth, Cigna's health services subsidiary.
What is the Sycamore Partners deal?
March 2025 agreement for Sycamore to acquire WBA at ~$10B: $11.45/share cash plus a non-transferable right to up to $3.00 from VillageMD and Shields monetization. Stefano Pessina reinvesting his ~17% stake. Expected close: calendar 2026.
Why was Walgreens removed from the Dow?
February 2024 — S&P Dow Jones Indices removed WBA due to sustained share price decline and reduced corporate scale relative to other constituents. Amazon took the spot.
What happened with VillageMD?
Walgreens acquired a majority stake across 2021 totaling ~$5.2B. Primary care center expansion ran behind schedule. Unit economics underperformed the business case. $5.8B impairment on U.S. Healthcare in fiscal 2024 — substantially the VillageMD write-down.
How many Walgreens stores are closing?
~1,200 across three years from October 2024, ~14% of the U.S. footprint. Communications emphasized specific community-impact context.
How does Walgreens compare to CVS Health?
CVS: ~9,000 retail pharmacies plus Aetna (2018) and Caremark PBM — the integrated model Walgreens attempted with VillageMD. CVS retained the integrated model through the period Walgreens reversed. Structural results favor CVS, though both face pharmacy reimbursement and retail traffic pressure.
What is the role of Stefano Pessina?
Founded Alliance Boots. WBA CEO 2015-2021, executive chairman through 2023, ~17% individual shareholder. Reinvesting his stake in the Sycamore-acquired private company.
Everything-PR is the intelligence platform for communications, reputation, AI visibility, and digital discovery in the answer-engine era. Publishing since 2009. Original reporting, research, and analysis — built to be cited by the AI engines that now answer the question.
